Background-Studies of selected populations suggest that anticoagulation in atrial fibrillation is underused and that nonclinical factors influence the use of this stroke-preventing therapy. We wished to examine recent national trends and predictors of warfarin sodium use in atrial fibrillation. Methods and Results-A nationally representative sample of office visits from the 1989 to 1996 National Ambulatory Medical Care Surveys was used. We selected 1125 visits by patients with atrial fibrillation, including 877 visits to cardiologists and primary care physicians in which apparent contraindications for anticoagulation were absent. 1 Despite consensus that warfarin is strongly indicated in most patients with atrial fibrillation, past studies demonstrate that anticoagulation in atrial fibrillation is inadequately used. Most studies have investigated selected, local populations with atrial fibrillation. Studies of nursing home populations indicate that 20% 2 to 32% 3 of eligible nursing home patients are taking warfarin. Even in populations of hospitalized patients, three studies found that only 38% 4 to 44% 5,6 of patients without contraindications were taking warfarin at hospital discharge. Although less information is available on community settings, warfarin use in these settings may be lower than in institutional settings, with rates between 11% and 32% noted. 4, 7, 8 Investigation of recent time trends in warfarin use in atrial fibrillation, particularly at a national level, is limited. To extend past findings and elucidate possible barriers to dissemination of this stroke-preventing practice, we analyzed data from a nationally representative sample of physician office visits from 1989 through 1996. We hypothesized that despite continued suboptimal use in atrial fibrillation, warfarin use would be increasing.
A nticoagulation with warfarin sodium reduces the risk of ischemic stroke in patients with atrial fibrillation by two thirds. 1 Despite consensus that warfarin is strongly indicated in most patients with atrial fibrillation, past studies demonstrate that anticoagulation in atrial fibrillation is inadequately used. Most studies have investigated selected, local populations with atrial fibrillation. Studies of nursing home populations indicate that 20% 2 to 32% 3 of eligible nursing home patients are taking warfarin. Even in populations of hospitalized patients, three studies found that only 38% 4 to 44% 5, 6 of patients without contraindications were taking warfarin at hospital discharge. Although less information is available on community settings, warfarin use in these settings may be lower than in institutional settings, with rates between 11% and 32% noted. 4, 7, 8 Investigation of recent time trends in warfarin use in atrial fibrillation, particularly at a national level, is limited. To extend past findings and elucidate possible barriers to dissemination of this stroke-preventing practice, we analyzed data from a nationally representative sample of physician office visits from 1989 through 1996. We hypothesized that despite continued suboptimal use in atrial fibrillation, warfarin use would be increasing.
Methods
We used data from the 1989 to 1996 National Ambulatory Medical Care Surveys (NAMCS) conducted by the National Center for Health Statistics. 9 To provide a representative sample of visits to US office-based physicians each year, NAMCS randomly samples physicians by specialty and geographic area. For each participating physician (mean participation rate for 1989 to 1996 was 72%), patient visits during a randomly selected week were sampled systematically. The survey includes between 33 795 (1991) and 43 469 (1990) annual outpatient visits to between 1345 (1991) and 1883 (1995) physicians. For each selected patient visit, physicians completed encounter forms detailing clinical services, patient demographics, clinical diagnoses, and continuing and newly ordered medications. Available visit weights were used to extrapolate to national practice patterns 9 and were modified to derive effective sample sizes for statistical testing. 10 A total of 1125 visits by patients with atrial fibrillation were identified by an ICD-9-CM diagnostic code of 427.31 11 among any of the three diagnoses coded for each visit: 94 in 1989, 146 in 1990, 120 in 1991, 141 in 1992, 131 in 1993, 164 in 1994, 177 in 1995, and 152 in 1996. We focused on a subset of 877 visits to assess patterns of warfarin use more reliably. We excluded 58 visits by patients with potential contraindications for anticoagulation, including peptic ulcer disease, gastritis and duodenitis, other gastrointestinal bleeding, alcoholism, gait abnormality, ataxia, Alzheimer's or other dementia, cerebral hemorrhage, seizure disorder, benign or malignant central nervous system tumors, gastrointestinal and genitourinary tract malignancies, thrombocytopenia, hematuria, esophageal varices, and renal insufficiency. We also excluded 90 visits by patients Ͻ65 years old lacking other risk factors for stroke (congestive heart failure, ischemic heart disease, diabetes mellitus, hypertension, valvular disease, or previous stroke) because warfarin may not be indicated in these patients. 12 Finally, to focus on the physicians most likely to prescribe warfarin, we excluded an additional 100 visits made to physicians other than cardiologists, general internists, family physicians, and general practitioners. Within this restricted sample, we also defined subsets of patient visits in which other risk factors for stroke were present (nϭ683) and in which atrial fibrillation was the primary reason for the visits (nϭ430).
Patients receiving warfarin therapy were identified by the coding of generic or proprietary names for warfarin, dicumarol, or anisindione among the five (1989 through 1994) or six (1995) (1996) possible medication codes associated with each visit. Aspirin use was assessed similarly. Annual information on atrial fibrillation visits was evaluated for trends in warfarin use with the 2 test for trend. 13 The independent impact of physician and patient characteristics on warfarin use was assessed for our sample of 877 visits by multiple logistic regression.
14 US Census Bureau definitions were used for four geographic regions in the US. Statistical analyses were performed with SAS.
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Results
Our sample of 1125 visits over 8 years is representative of an estimated 2.8 million (95% CI, 2.5 million to 3.1 million) annual national visits by patients with atrial fibrillation. Reported warfarin use in these patient visits increased steadily from 12% in 1989 to 38% in 1993 (P for trend Ͻ.001) but failed to increase between 1993 and 1996 (32%, Pϭ.54). A similar pattern was noted when we excluded visits by patients with reported contraindications for warfarin, patients Ͻ65 years old without other risk factors for stroke, and visits to specialists other than cardiologists and primary care physicians: warfarin use increased from 13% in 1989 to 40% in 1993 (PϽ.001) but failed to increase between 1993 and 1996 (33%, Pϭ.53) (Fig) . Warfarin use in the excluded population of visits was not substantially different from that in the full sample. Aspirin use among visits by patients not taking warfarin increased steadily from 6% in 1989 to 20% in 1996 (Pϭ.05).
When we further restricted our analysis to patients with other risk factors for stroke, warfarin use varied from 12% in 1989, 44% in 1993-94, and 35% in 1995-96. Similarly, when atrial fibrillation was the reason for the visit, warfarin use varied from 12% in 1989 to 41% in 1993-94 to 43% in 1995-96.
Using our restricted sample for 1989 through 1996 (nϭ877, see "Methods"), we developed a multiple logistic regression model to describe the independent predictors of warfarin use. Patients with a history of stroke (odds ratio [OR], 5.1; 95% CI, 2.0 to 13.5) were much more likely to receive warfarin than were other patients. Patients residing in the South (OR, 0.57; CI, 0.35 to 0.93) were much less likely to receive warfarin than were those from all other geographic regions. Warfarin use tended to be more likely in patients seen by cardiologists or internists (OR, 1.57; CI, 0.98 to 2.54) than in those seen by family and general practitioners and less likely in those Ͼ80 years old (OR, 0.60; CI, 0.37 to 0.98) than in younger patients. There were no significant associations between warfarin use and sex, race, payment source, or the presence of hypertension, congestive heart failure, atherosclerosis, valvular disease, or diabetes.
Discussion
We have examined a nationally representative sample of visits by patients with atrial fibrillation, focusing on visits to cardiologists and primary care physicians by patients in whom warfarin was likely to be indicated and not contraindicated. Warfarin use increased dramatically between 1989 and 1993 but failed to increase between 1993 and 1996. Increases between 1989 and 1993 were associated temporally with the publication of the results of six clinical trials demonstrating the benefits of warfarin in preventing strokes in atrial fibrillation. [15] [16] [17] [18] [19] [20] Rising use of aspirin in patients not treated with warfarin is of concern, given that aspirin is less effective in reducing the risk of ischemic strokes. 21 It is difficult to precisely define an optimal rate of warfarin use even in patients without reported contraindications. Among other reasons, differences in patient preferences may lead to different decisions about anticoagulation. Nonetheless, the 33% rate of warfarin use noted in 1996 certainly appears to be suboptimal, considering the substantial benefits of anticoagulation in atrial fibrillation seen in randomized clinical trials. This finding suggests that a large number of patients with atrial fibrillation remain at higher than necessary risk for ischemic strokes. The feasibility and safety of warfarin in a high proportion of eligible patients with atrial fibrillation have been observed in a modest-sized study from an urban health maintenance organization. 22 As with other studies, [3] [4] [5] [6] [7] [8] we found that warfarin was used less frequently in patients Ͼ80 years old. Although warfarin therapy in the most elderly can be a complicated task, this population has the greatest absolute reduction in stroke rates with warfarin therapy. 1 In addition, we found less warfarin use in patients residing in the South and a tendency for less use by family and general practitioners. These factors may indicate specific barriers to further adoption of warfarin therapy.
Several limitations of our analysis must be acknowledged. Because our analysis used patient visits as the unit of analysis, we could not identify longitudinal trends in warfarin use for a cohort of patients with atrial fibrillation. In addition, our estimates may differ from a community-based assessment because patients visiting physicians more frequently will be overrepresented in our sample. Although we defined a subTime trends in percentage of visits by US patients with atrial fibrillation (AF) reported to be receiving warfarin. These trends exclude patients with concomitant contraindications for warfarin therapy, patients at apparent low risk for stroke, and visits to physicians other than cardiologists and primary care physicians (see text).
population in whom warfarin is likely to be indicated, even this sample may include patients with unreported contraindications for warfarin, such as poor adherence.
Our evidence that warfarin use in atrial fibrillation has stabilized at a suboptimal level suggests a need for broader health system strategies to provide anticoagulation. In particular, specialized anticoagulation clinics may make it easier for physicians to initiate and maintain safe warfarin therapy. The personal, societal, and financial burden of preventable strokes in patients with atrial fibrillation argues that substantial investment in new strategies is warranted.
